Class IIa HDACs forced degradation allows resensitization of oxaliplatin-resistant FBXW7-mutated colorectal cancer

Molecular Oncology · 2026 · 20(3):637–667

• Oncology
• Drug Resistance
• Translational Research

Cristina Degrassi co-authored the study with MTTlab listed as affiliation.

View publication